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New active agents are needed to develop effective systemic therapy against Stage IIIB-IV non-small cell 
lung cancer (NSCLC). The aim of the present study was to assess the efficacy and toxicity of gemcitabine, 
a novel nucleoside analogue with significant preclinical activity, as a single-agent therapy. 
Forty-three patients with previously untreated Stage IIIB-IV NSCLC were included. Gemcitabine 
was administered intravenously over 30 min on Days 1, 8 and 15 of each 28-day cycle at a dose of 
1250 mg me2. 
Thirty-seven patients were evaluable for response. There were seven partial responses giving an overall 
response rate of 19% (95% confidence interval 8-35%). Median duration of response was 6 months. 
One-year survival and median survival for all patients were 33% and 8 months, respectively. Toxicity of 
the treatment was mild. World Health Organization (WHO) Grade 34 leukopenia was detected in 11% 
of the patients. Mild (WHO Grade l-2) nausea was the most frequent subjective side-effect with a rate 
of 82%. Mild rash and peripheral oedema were typical side-effects of gemcitabine with rates of 19 and 
9%, respectively. 
In conclusion, single-agent gemcitabine is an active and well-tolerated treatment for Stage IIIB-IV 
NSCLC patients. 
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Introduction 
It is estimated that more than 80% of patients with 
non-small cell lung cancer (NSCLC) have metastases 
at the time of diagnosis, and systemic therapy is 
therefore the only curative potential (1). Without 
treatment, the median survival of these patients has 
been reported to be from 4.5 to 7.5 months (2). In 
recent meta-analyses, cisplatin-based polycemo- 
therapy has been shown to significantly increase the 
survival of patients with both locally advanced and 
metastatic disease (3,4). However, this increase in 
median survival was only 1.5 months when compared 
with best supportive care (4). In the meta-analysis by 
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Souquet et al., patients responding to therapy also 
had an improvement in quality of life (3). This can be 
explained by the disappearance of tumour-related 
symptoms. However, the side-effects of combination 
chemotherapy using cisplatin are well known and, 
therefore, new, better tolerated and more effective 
agents are required to improve results in the treat- 
ment of Stage IIIB-IV NSCLC. 
Gemcitabine is a novel anticancer agent. It is an 
analogue of deoxycytidine, and resembles cytarabine 
structurally. Unlike cytarabine, gemcitabine has 
activity against solid tumours such as ovarian cancer, 
bladder cancer, breast cancer and head and neck 
cancer. Lilenbaum and Green reviewed several Phase 
II trials of gemcitabine in the treatment of NSCLC 
that had been reported in abstract form (5). They 
presented 211 patients with 44 responders (20.9%). 
Single-agent activity of gemcitabine exceeding 20% 
has also been documented in further studies (6). The 
present study was conducted to assess the activity and 
side-effects of gemcitabine in patients with previously 
untreated Stage IIIB-IV NSCLC. 
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TABLE 1. Patient characteristics 
n 
Males 
Females 
Age (years) 
Mean 
Range 
Histology 
Adeno 
Squamous 
Large 
Clinical stage 
IIIB 
IV 
Performance status (WHO Grade) 
0 
1 
2 
43 
32 
11 
57 
39-76 
24 
13 
6 
5 
38 
2 
35 
6 
WHO, World Health Organization. 
Patients and Methods 
Between February 1992 and January 1995, 43 
patients (32 males and 11 females) with Stage IIIB-IV 
histologically or cytologically confirmed NSCLC 
entered the study. Patient characteristics are given in 
Table 1. Entry criteria included: performance status 
of World Health Organization (WHO) Grade O-2, 
age above 18 years, estimated life expectancy of at 
least 12 weeks, measurable or evaluable disease, no 
prior chemotherapy, no radiotherapy if the lesion for 
tumour measurements was located in the irradiated 
area, adequate bone marrow reserve (haemoglobin 
2 100 g l- ‘, white blood cell count (WBC count) 
23.0 x 101-1, platelets 2 100 x lo9 1 - ‘), and 
adequate liver and renal function. Patients with 
symptoms of severe pulmonary disease, active cardiac 
disease or significant neurologic disorders, such as 
central nervous system metastases, as well as patients 
with uncontrolled hypercalcaemia, were excluded. All 
patients gave their written consent before starting the 
treatment. The study was approved by the Ethics 
Committee of the Division of Pulmonary Medicine 
and Clinical Physiology, Department of Medicine at 
the Helsinki University Central Hospital, Finland. 
Gemcitabine 1250 mg was administered intra- 
venously over 30 min on Days 1, 8 and 15 of each 
28-day cycle. A cycle was thus defined as three 
consecutive weeks of treatment followed by a week of 
rest. The protocol allowed a maximum of six cycles. 
In case of no toxicities after the first cycle, a 20% dose 
escalation was allowed for the first nine patients in 
the study. Dose modifications were made according 
to haematologic parameters. The dose was reduced to 
75% if WBC count was 1.0 - 1.9 x lo9 1 - ’ and/or 
platelet count 50-99 x lo9 l- ‘, and omitted if WBC 
count c 1-O x IO9 I- ’ and/or platelet count ~50 x 
lo9 1 - ‘. A treatment which had to be postponed for 3 
weeks because of toxicity was discontinued. A mini- 
mum of two cycles of gemcitabine were required for 
response evaluation, which was assessed according to 
Union Internationale Centre le Cancer (UICC) 
response criteria (7). Toxicity was evaluated using 
WHO criteria. Chi-squared test was used for analysis 
of statistical differences among responders. 
Results 
One to six cycles (mean 3.2) of gemcitabine were 
given to each patient. Nine (7%) cycles were given at 
120% escalated doses. Seven out of 137 (5%) cycles 
were given at 75% reduced doses. Leukopenia was 
the main reason for dose reductions in all cases. 
Twenty patients received other treatments after dis- 
continuation of gemcitabine. Six of them received 
radiotherapy alone, 13 patients received another 
chemotherapy regimen and one patient received both 
radio- and chemotherapy after gemcitabine. 
RESPONSE TO TREATMENT 
Thirty-seven patients were evaluable for response. 
There were no complete responses. Seven patients 
reached partial response (PR) which makes an objec- 
tive response rate of 19% [95% confidence interval 
(CI) g-35%]. In four patients, responses were detected 
using chest X-ray after two cycles of gemcitabine, and 
confirmed by computerized tomography (CT) after 
three to four cycles, i.e. when CT was performed for 
the first time after starting gemcitabine. In the other 
three patients, PR was registered after four cycles. 
Median duration of response was 6 months with a 
range of 2-8 months. Five of the seven responders 
were men. The tumour histology of the responders 
included: three adenocarcinomas, three squamous cell 
carcinomas and one large cell carcinoma. (Table 2). 
There were no statistically significant differences 
between responders in terms of sex or tumour histol- 
ogy. Two of the responders had Stage IIIB disease 
while the others had Stage IV. Partial response in the 
five patients with Stage IV disease was seen in pri- 
mary tumours as well as in the metastases. Both 
patients with the best performance status (WHO 
Grade 0) had no change (NC) at tumour evaluation. 
Six of the responders had WHO Grade 1 and one had 
WHO Grade 2. 
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TABLE 2. Response by tumour histology, clinical stage 
and performance status 
Total PR NC PD 
Histology 
Adeno 
Squamous 
Large 
Clinical stage 
IIIB 
IV 
Performance status 
0 
L 
23 3 14 6 
10 3 2 5 
4 1 1 2 
5 2 3 0 
32 5 14 13 
2 0 2 0 
30 6 13 11 
5 1 2 2 
PR, partial response; NC, no change; PD, progressive 
disease. 
Six patients (all with Stage IV disease) were not 
evaluable for response due to early death (one 
patient), patient decision to discontinue at the end 
of first cycle (three patients) and protocol violation 
(two patients). The patients who decided to give up 
the treatment had experienced several side-effects 
including WHO Grade 2 anaemia, WHO Grade 2 
drug-related fever and deep venous thrombosis. One 
case of protocol violation was the result of gem- 
citabine treatment being postponed too many times 
before the second cycle. Protocol violation also 
occurred in a patient who had received prior chemo- 
and radiotherapy. 
PATIENT SURVIVAL 
All patients, including the patients who received other 
treatments after discontinuation of gemcitabine, were 
evaluated in the survival analysis. Median survival for 
all patients and by response (PR/NC/PD) were 8 and 
18/l O/5 months, respectively. One-year survival was 
33% for all patients and 71/41/15% for PR/NC/PD, 
respectively. Median survival by clinical stage (Stages 
III and IV) and performance status (WHO Grades 
O-2) were 18 + and 8 months, and 11,9 and 4 months, 
respectively. In fact, five patients are still alive. 
TOXICITY 
All patients were evaluable for toxicity. Nine patients 
(21%) were totally free from haematological toxicity. 
World Health Organization Grade 2 leukopaenia was 
the most common finding, occurring in 33% of 
patients, whereas 11% experienced Grade 334 leuko- 
penia. Anaemia was the second most common sign of 
haematological toxicity, and Grade 1 and 2 anaemia 
were equally common, each occurring in 21% of 
patients. World Health Organization Grade 1 throm- 
bocytopenia was detected in 12% of all patients, and 
the rate of Grade 2 thrombocytopenia was 5%. 
Seven patients (16%) suffered no non- 
haematological toxicity. The most common subjective 
side-effect was nausea, which was usually mild. World 
Health Organization Grade 1 and 2 nausea rates were 
70 and 12%, respectively, and were manageable with 
standard anti-emetics. World Health Organization 
Grade 1 and 2 fever rates were both 21%. Rash (WHO 
Grade 1) was reported in 19% of the patients, and 
peripheral oedema in the limbs was experienced by 
9% of the patients. No severe renal toxicity, gastro- 
intestinal toxicity or neurotoxicity was observed. 
There were no deaths directly related to gemcitabine. 
Discussion 
The objective response rate achieved in this study, i.e. 
19% (95% CI 8-35%), is similar to previous reports. 
Anderson et al. reported a response rate of 20% (95% 
CI 12-31%) in 82 patients with NSCLC (8). Fifty- 
four patients received 800 mg m - 2 week - ’ and 28 
patients received 1000 mg m - 2 week- ’ for 3 weeks 
followed by a week of rest. The most common 
toxicities were WHO Grade 3 nausea in 38%, severe 
neutropenia (WHO Grade 34) in 22% of the patients 
and peripheral oedema in 40% of the patients. In the 
latest report by the same group (9) the response rate 
remained the same although the patient population 
was expanded to 332 evaluable patients with 
advanced, inoperable NSCLC. Thirteen percent of 
the patients had Stage IIIA disease. The dose of 
gemcitabine used was 800-1250 mg m - 2. Abratt 
et al. reported an objective response rate of 20% 
which included two complete responses in 84 patients 
with Stage IIIB-IV NSCLC (10). The patients 
received gemcitabine at doses of 1000-1250 mg m- ‘. 
In an international multicentre study of 161 inoper- 
able Stage III-IV NSCLC patients using higher doses 
(i.e. 1250 mg mm2), the response rate was 22% (1 l), 
but only three achieved complete response. All this 
suggests that escalating the starting dose from 800 to 
1250 mg me2 does not increase response rate. 
Median survival for all patients in the present study 
was 8 months and the 1-yr survival rate was 33%. 
These numbers are comparable with the reports by 
Anderson and Abratt (9,lO). However, nearly half of 
the present study patients received other treatments 
after gemcitabine which, of course, may affect the 
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survival. After comparing the patient characteristics 
of the responders with non-responders, no factor 
could be found to favour better tumour response or 
survival. 
The toxicity analysis based on 137 chemotherapy 
cycles showed treatment to be well tolerated. Haema- 
tological toxicity was mild. Severe, i.e. WHO Grade 
334, toxicity was only detected in leukocyte counts 
(11%). In the Anderson study, WHO Grade 3-4 
leukopenia was detected in 7%, WHO Grade 34 
anaemia was detected in 5%, and WHO Grade 
334 thrombocytopenia was detected in 2% of the 
patients evaluable for toxicity (8). Abratt et al. 
reported even lower haematological toxicity i.e. 
WHO Grade 3-4 leukopenia in 1% and WHO Grade 
34 thrombocytopenia in 0.2% of the patients (lo), 
even though the dose of gemcitabine was higher than 
in the study by Anderson et al. 
Non-haematological toxicity was also mild in the 
present study. Sixteen percent of the patients were 
totally free from subjective side-effects. The most 
common side-effect was nausea, which was less severe 
(WHO Grade l-2) but slightly more frequent (82%) 
in the present study patients when compared with 
Anderson’s (WHO Grade 1-3, 78%) and Abratt’s 
(WHO Grade l-3, 68%) studies (8,lO). 
Peripheral oedema and rash seem to be typical 
side-effects of gemcitabine. In the present study, these 
symptoms were mild (WHO Grade 1) and not as 
common as in previous reports. Peripheral oedema 
was found in 9% of the present study patients as 
compared with 40% in Anderson’s and 42% in 
Abratt’s studies. Rash was detected in only 19% 
of the present study patients but it was reported in 
39 and 44% of Anderson’s and Abratt’s studies, 
respectively (8,lO). 
Early responses were achieved frequently by using 
high doses (1250 mg mw2) of gemcitabine; in four 
cases after two cycles of gemcitabine, and in three 
cases after four cycles. There were no responses after 
further cycles, which implies that continuing treat- 
ment beyond four cycles in non-responders is not 
indicated. No unexpected toxicity was observed in the 
present study patients, while some known, frequent 
side-effects, e.g. peripheral oedema and rash, were 
uncommon. Mild toxicity could provide an oppor- 
tunity to escalate the starting dose, up to 2000 mg 
m- 2, and further studies are required to assess the 
optimal dose of gemcitabine. 
It is concluded that gemcitabine is active as a single 
agent against Stage IIIB-IV NSCLC, but due to the 
lack of complete responses and the limited duration 
of responses, gemcitabine should be used in combina- 
tion with other drugs. The low toxicity of gemcitabine 
encourages further studies of combinations with 
other active agents, which could be taxanes or 
campthothecine analogues. 
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